Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NYSEAMERICAN:ARMP

Armata Pharmaceuticals 3/25/2026 Earnings Report

Armata Pharmaceuticals logo
$8.94 -0.12 (-1.35%)
As of 12:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Armata Pharmaceuticals EPS Results

Actual EPS
-$3.42
Consensus EPS
-$0.19
Beat/Miss
Missed by -$3.23
One Year Ago EPS
N/A

Armata Pharmaceuticals Revenue Results

Actual Revenue
$1.09 million
Expected Revenue
$0.74 million
Beat/Miss
Beat by +$345.00 thousand
YoY Revenue Growth
N/A

Armata Pharmaceuticals Announcement Details

Quarter
Date
3/25/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Armata Pharmaceuticals Earnings Headlines

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
 |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68425808-armata-pharmaceuticals-inc-armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-008.htm
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
May 7 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines. But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.tc pixel
May 7 at 1:00 AM  |  Behind the Markets (Ad)
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
May 4 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-structural-biology-publication-in-communications-biology-302760348.html
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
April 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-appointment-of-biopharmaceutical-commercial-executive-daniel-b-gilmer-phd-to-its-board-of-directors-302753455.html
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/armata-pharmaceuticals-armp-price-target-increased-by-16-67-to-17-85/ar-AA210w9K
See More Armata Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email.

About Armata Pharmaceuticals

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats.

Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.

View Armata Pharmaceuticals Profile
Earnings Tools